GRAL
GRAIL, Inc. Common StockGRAL
GRAL
About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Employees: 1,000
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
91% more call options, than puts
Call options by funds: $21M | Put options by funds: $11M
29% more capital invested
Capital invested by funds: $476M [Q4 2024] → $613M (+$137M) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 86
5% less funds holding
Funds holding: 322 [Q4 2024] → 306 (-16) [Q1 2025]
8.46% less ownership
Funds ownership: 79.23% [Q4 2024] → 70.77% (-8.46%) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 57
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$43
6%
upside
Avg. target
$43
6%
upside
High target
$43
6%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Kyle Mikson | 6%upside $43 | Buy Maintained | 14 May 2025 |
Financial journalist opinion
Based on 4 articles about GRAL published over the past 30 days
Positive
WSJ
2 weeks ago
The Holy Grail of Automation: Now a Robot Can Unload a Truck
Technology breakthroughs are allowing DHL and other companies to automate the laborious, injury-prone work of loading and unloading.
Positive
Market Watch
3 weeks ago
Grail Shares Jump on Promising Results for Galleri Study
Shares of Grail climbed after the company said the second study of its Galleri multi-cancer early detection test provided even more promising results than the first.
Neutral
PRNewsWire
3 weeks ago
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif. , June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study.
Neutral
Schaeffers Research
4 weeks ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Positive
MarketBeat
1 month ago
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.
Neutral
PRNewsWire
1 month ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
Neutral
PRNewsWire
1 month ago
GRAIL to Present at Jefferies Global Healthcare Conference 2025
MENLO PARK, Calif. , May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m.
Negative
Benzinga
1 month ago
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Neutral
Seeking Alpha
1 month ago
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Bob Ragusa - CEO Aaron Freidin - CFO Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Andy Partridge - Chief Commercial Officer Conference Call Participants Subbu Nabi - Guggenheim Partners Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Kyle Mikson - Canaccord Operator Good day, ladies and gentlemen. And welcome to the GRAIL First Quarter 2025 Earnings Call.
Neutral
PRNewsWire
1 month ago
GRAIL Reports First Quarter 2025 Financial Results
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif. , May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.
Charts implemented using Lightweight Charts™